Key points are not available for this paper at this time.
The recent public announcement by TIGR and Perkin-Elmer that they intend to form a new company whose goal is to sequence the human genome four years faster and at lower cost than the government-backed Human Genome Project caught the immediate attention of the community. Venter et al. now describe the scientific rationale for their proposal and outline the business plan of the company.
Venter et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: